Cytokinetics (CYTK) Expected to Announce Earnings on Thursday

Cytokinetics (NASDAQ:CYTK) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Cytokinetics to post earnings of ($1.29) per share and revenue of $14.26 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $48.14 on Tuesday. The company has a market cap of $5.68 billion, a price-to-earnings ratio of -8.95 and a beta of 0.83. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The firm has a 50 day simple moving average of $47.27 and a 200 day simple moving average of $51.48. Cytokinetics has a one year low of $40.53 and a one year high of $81.36.

Insider Buying and Selling

In other Cytokinetics news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $50.76, for a total value of $253,800.00. Following the transaction, the chief executive officer now directly owns 397,678 shares of the company’s stock, valued at approximately $20,186,135.28. This trade represents a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $45.92, for a total transaction of $91,840.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at $5,329,980.32. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,822 shares of company stock valued at $1,127,848 over the last ninety days. 3.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CYTK shares. Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Thursday, February 6th. Citigroup started coverage on shares of Cytokinetics in a research report on Friday, February 7th. They issued a “buy” rating and a $86.00 price target for the company. Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price target for the company. Evercore ISI upgraded shares of Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.00.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.